All In MedTech

Device Trial Radar · NCT03176225

Evaluate Safety and Effectiveness of XenoSure Biological Patch in the Application of Cardiac Repair

Random, Controlled, Single-blinded, Multi-center and Non-inferiority Clinical Study to Evaluate Safety and Effectiveness of XenoSure Biological Patch in the Application of Cardiac Repair

Last checked: Nov 20, 2026Latest source record: Mar 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 142 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

142

Actual

Start

Aug 15, 2017

Primary completion

Nov 15, 2020

Study completion Feb 15, 2024

Sponsor

Lead sponsor
LeMaitre VascularNot on our public-company list
Sponsor type
Industry
First posted
Jun 5, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, up to 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to collect safety and effectiveness data to support cardiac repair indication of XenoSure biologic patch. This trial is performed to meet the China FDA regulations for this kind of device. The clinical trial will be performed solely inside China under GCP regulation and all applicable China regulations on medical device clinical trial.

Conditions

  • Heart Diseases

Interventions

  • Open heart surgery to address the heart diseaseProcedure

    The patient will first have open heart surgery to achieve access to the diseased site in the heart

  • Close the defects with XenoSure PatchDevice

    The heart defects, such as ASD (Atrial Septal Defect) or VSD (Ventricular Septal Defect ), are closed with LeMaitre XenoSure Patch.

  • Close the defects with Chest Polyester PatchDevice

    The heart defects, such as ASD (Atrial Septal Defect) or VSD (Ventricular Septal Defect ), are closed with a Polyester Patch made by Shanghai Chest Medical Technology Co.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Leakage rate at 6 month post-procedure measured by ultrasoundTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.